Article
Adapting clinical paradigms to the challenges of cancer clonal evolution.
The American journal of pathology - 1 Jun 2013
Murugaesu Nirupa, Chew Su Kit, Swanton Charles
Abstract excerpt
Emerging evidence suggests that cancer branched evolution may affect biomarker validation, clinical outcome, and emergence of drug resistance. The changing spatial and temporal nature of cancer subclonal architecture during the disease course suggests the need for longitudinal prospective studies of cancer evolution and robust and clinically implementable pathologic definitions of intratumor heterogeneity,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
